Physician profile
Dillon Noland
NPI 1407315401
$6,027.16
in general payments reported to CMS, 2019-2025
25 companies · $4,346 in 2025
The $4,346 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $200 · 2023: $535 · 2024: $946 · 2025: $4,346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,639 · Food and Beverage: $1,942 · Travel and Lodging: $1,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,638.98 |
| Food and Beverage | $1,941.96 |
| Travel and Lodging | $1,246.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,746.59 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $569.84 | 2022-2025 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $297.87 | 2023-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $275.56 | 2023-2025 | Tezspire, Fasenra, Farxiga |
| Merck Sharp & Dohme LLC | $184.39 | 2023-2025 | Zerbaxa, Winrevair, Dificid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.69 | 2022-2025 | Ofev, Jascayd |
| United Therapeutics Corporation | $147.95 | 2022-2025 | Tyvaso, Tyvaso |
| Genzyme Corporation | $134.85 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.58 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $66.11 | 2024 | Acthar |
| Philips North America LLC | $61.09 | 2023-2024 | (Ak6) Vest Therapy |
| Pulmonx Corporation | $31.70 | 2024 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Amgen INC. | $25.64 | 2024 | Tavneos |
| Calliditas Therapeutics US INC. | $25.37 | 2025 | Tarpeyo |
| Abbvie INC. | $22.08 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $21.29 | 2024 | |
| Eisai INC. | $21.07 | 2024 | |
| Sandoz INC. | $19.96 | 2023 | Treprostinil |
| Genentech USA, INC. | $18.99 | 2024 | Xofluza |
| Shionogi INC | $18.95 | 2023 | Fetroja |
| Inogen, INC. | $15.95 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Janssen Pharmaceuticals, INC | $15.53 | 2022 | |
| Blueprint Medicines Corporation | $14.32 | 2024 | Ayvakit |
| Mylan Specialty L.P. | $13.26 | 2024 | Yupelri |
| Janssen Biotech, INC. | $7.53 | 2024 | Talvey, Tecvayli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dillon Noland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.